The BCL-2 gene is the prototype of a newly described family of oncogenes involved in
tumorigenesis by blocking apoptosis, or programmed cell death. Overexpression of BCL-2
protein was originally described in follicular
B-cell lymphomas bearing the 14;18 translocation. BCL-2 overexpression has also been described in other
lymphomas and more rarely in
neoplasms outside the lymphoid tissue. The aim of this paper is to determine the immunohistochemical expression of BCL-2 in
intradermal nevi and primary invasive and metastatic
melanoma.
Formalin-fixed and
paraffin-embedded tissues from 4 cutaneous
melanoma metastases, 10 primary invasive
melanomas, and 10 intradermal
melanocytic nevi were immunolabeled with
monoclonal antibodies directed against BCL-2
protein (Dako, clone 124) and
Ki-67 antigen (Amac, clone MIB-1), after
antigen retrieval techniques. Morphologically normal epidermal melanocytes expressed BCL-2, as did
nevi and melanomas in virtually all cells. However, whereas the labeling in normal melanocytes and
nevus cells showed a uniformly strong reactivity,
melanoma cells showed a variable but mainly weak reactivity.
Ki-67 antigen expression was restricted to
melanomas. The widespread expression of BCL-2 suggests that this
oncoprotein cannot be involved in the malignant transformation of melanocytic cells. It seems likely that the decreased BCL-2 expression detected in
melanomas may reflect one further step of
tumor progression in melanocytic
neoplasms.